Allarity Therapeutics Inc... (ALLR)
NASDAQ: ALLR
· Real-Time Price · USD
1.47
-0.05 (-3.29%)
At close: Sep 17, 2025, 3:59 PM
1.52
3.30%
After-hours: Sep 17, 2025, 07:58 PM EDT
-3.29% (1D)
| Bid | 1.43 |
| Market Cap | 21.49M |
| Revenue (ttm) | 6K |
| Net Income (ttm) | -24.66M |
| EPS (ttm) | 5.75 |
| PE Ratio (ttm) | 0.26 |
| Forward PE | -1.96 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 1.52 |
| Volume | 492,912 |
| Avg. Volume (20D) | 7,265,520 |
| Open | 1.47 |
| Previous Close | 1.52 |
| Day's Range | 1.44 - 1.58 |
| 52-Week Range | 0.61 - 2.96 |
| Beta | 0.15 |
| Ex-Dividend Date | n/a |
About ALLR
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ALLR
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ALLR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
+51.92%
Allarity Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
1 month ago
+9.8%
Allarity Therapeutics shares are trading higher after Ascendiant Capital initiated coverage on the stock with a Buy rating and announced a price target of $9.
3 weeks ago · proactiveinvestors.com
Allarity Therapeutics shares pop as ovarian cancer therapy recieves FDA Fast Track DesignationAllarity Therapeutics (NASDAQ:ALLR) shares more than doubled after the pharmaceutical firm annoucned that its investigational therapy for advanced ovarian cancer, stenoparib, has received Fast Track D...